163 related articles for article (PubMed ID: 34555844)
21. In vitro expansion of CD34(+)CD38(-) cells under stimulation with hematopoietic growth factors on AGM-S3 cells in juvenile myelomonocytic leukemia.
Sakashita K; Kato I; Daifu T; Saida S; Hiramatsu H; Nishinaka Y; Ebihara Y; Ma F; Matsuda K; Saito S; Hirabayashi K; Kurata T; Uyen LT; Nakazawa Y; Tsuji K; Heike T; Nakahata T; Koike K
Leukemia; 2015 Mar; 29(3):606-14. PubMed ID: 25102944
[TBL] [Abstract][Full Text] [Related]
22. Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia.
Gandre-Babbe S; Paluru P; Aribeana C; Chou ST; Bresolin S; Lu L; Sullivan SK; Tasian SK; Weng J; Favre H; Choi JK; French DL; Loh ML; Weiss MJ
Blood; 2013 Jun; 121(24):4925-9. PubMed ID: 23620576
[TBL] [Abstract][Full Text] [Related]
23. Functional evaluation of circulating hematopoietic progenitors in Noonan syndrome.
Timeus F; Crescenzio N; Baldassarre G; Doria A; Vallero S; Foglia L; Pagliano S; Rossi C; Silengo MC; Ramenghi U; Fagioli F; Cordero di Montezemolo L; Ferrero GB
Oncol Rep; 2013 Aug; 30(2):553-9. PubMed ID: 23756559
[TBL] [Abstract][Full Text] [Related]
24. Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia.
Shigemura T; Matsuda K; Kurata T; Sakashita K; Okuno Y; Muramatsu H; Yue F; Ebihara Y; Tsuji K; Sasaki K; Nakahata T; Nakazawa Y; Koike K
Br J Haematol; 2019 Oct; 187(2):163-173. PubMed ID: 31222725
[TBL] [Abstract][Full Text] [Related]
25. Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis.
Chan G; Kalaitzidis D; Usenko T; Kutok JL; Yang W; Mohi MG; Neel BG
Blood; 2009 Apr; 113(18):4414-24. PubMed ID: 19179468
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia.
Bunda S; Kang MW; Sybingco SS; Weng J; Favre H; Shin DH; Irwin MS; Loh ML; Ohh M
Cancer Res; 2013 Apr; 73(8):2540-50. PubMed ID: 23400592
[TBL] [Abstract][Full Text] [Related]
27. VAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease.
An W; Mohapatra BC; Zutshi N; Bielecki TA; Goez BT; Luan H; Iseka F; Mushtaq I; Storck MD; Band V; Band H
Oncotarget; 2016 Sep; 7(37):59006-59016. PubMed ID: 27449297
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneous disease-propagating stem cells in juvenile myelomonocytic leukemia.
Louka E; Povinelli B; Rodriguez-Meira A; Buck G; Wen WX; Wang G; Sousos N; Ashley N; Hamblin A; Booth CAG; Roy A; Elliott N; Iskander D; de la Fuente J; Fordham N; O'Byrne S; Inglott S; Norfo R; Salio M; Thongjuea S; Rao A; Roberts I; Mead AJ
J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33416891
[TBL] [Abstract][Full Text] [Related]
29. Yolk sac erythromyeloid progenitors expressing gain of function PTPN11 have functional features of JMML but are not sufficient to cause disease in mice.
Tarnawsky SP; Yoshimoto M; Deng L; Chan RJ; Yoder MC
Dev Dyn; 2017 Dec; 246(12):1001-1014. PubMed ID: 28975680
[TBL] [Abstract][Full Text] [Related]
30. Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.
Xu D; Liu X; Yu WM; Meyerson HJ; Guo C; Gerson SL; Qu CK
J Exp Med; 2011 Sep; 208(10):1977-88. PubMed ID: 21930766
[TBL] [Abstract][Full Text] [Related]
31. Patterns of hematopoietic lineage involvement in children with neurofibromatosis type 1 and malignant myeloid disorders.
Miles DK; Freedman MH; Stephens K; Pallavicini M; Sievers EL; Weaver M; Grunberger T; Thompson P; Shannon KM
Blood; 1996 Dec; 88(11):4314-20. PubMed ID: 8943868
[TBL] [Abstract][Full Text] [Related]
32. Mutational landscape of Juvenile Myelomonocytic Leukemia (JMML)-A real-world context.
Nathany S; Chatterjee G; Ghai S; Moulik NR; Shetty D; Subramanian PG; Tembhare P; Gujral S; Dhamne C; Banavali S; Narula G; Patkar N
Int J Lab Hematol; 2021 Dec; 43(6):1531-1538. PubMed ID: 34387930
[TBL] [Abstract][Full Text] [Related]
33. Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia.
Chang TY; Dvorak CC; Loh ML
Blood; 2014 Oct; 124(16):2487-97. PubMed ID: 25163700
[TBL] [Abstract][Full Text] [Related]
34. Effects of JAK1/2 inhibition on bone marrow stromal cells of myeloproliferative neoplasm (MPN) patients and healthy individuals.
Zacharaki D; Ghazanfari R; Li H; Lim HC; Scheding S
Eur J Haematol; 2018 Jul; 101(1):57-67. PubMed ID: 29645296
[TBL] [Abstract][Full Text] [Related]
35. Interleukin (IL)-10, but not IL-4 or IL-13, inhibits cytokine production and growth in juvenile myelomonocytic leukemia cells.
Iversen PO; Hart PH; Bonder CS; Lopez AF
Cancer Res; 1997 Feb; 57(3):476-80. PubMed ID: 9012477
[TBL] [Abstract][Full Text] [Related]
36. EVI-1 gene expression in myeloid clonogenic cells from juvenile myelomonocytic leukemia (JMML).
Privitera E; Longoni D; Brambillasca F; Biondi A
Leukemia; 1997 Dec; 11(12):2045-8. PubMed ID: 9447818
[TBL] [Abstract][Full Text] [Related]
37. Lineage-dependent skewing of loss of heterozygosity (LOH) of KRAS gene in a case of juvenile myelomonocytic leukemia.
Tokuda K; Eguchi-Ishimae M; Iwabuki H; Kawakami S; Tauchi H; Ishii E; Eguchi M
Eur J Haematol; 2015 Feb; 94(2):177-81. PubMed ID: 24766281
[TBL] [Abstract][Full Text] [Related]
38. Myeloproliferative neoplasm stem cells.
Mead AJ; Mullally A
Blood; 2017 Mar; 129(12):1607-1616. PubMed ID: 28159736
[TBL] [Abstract][Full Text] [Related]
39. Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms.
Grockowiak E; Korn C; Rak J; Lysenko V; Hallou A; Panvini FM; Williams M; Fielding C; Fang Z; Khatib-Massalha E; García-García A; Li J; Khorshed RA; González-Antón S; Baxter EJ; Kusumbe A; Wilkins BS; Green A; Simons BD; Harrison CN; Green AR; Lo Celso C; Theocharides APA; Méndez-Ferrer S
Nat Cancer; 2023 Aug; 4(8):1193-1209. PubMed ID: 37550517
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of the Gab2/PI3K/mTOR signaling ameliorates myeloid malignancy caused by Ptpn11 (Shp2) gain-of-function mutations.
Liu W; Yu WM; Zhang J; Chan RJ; Loh ML; Zhang Z; Bunting KD; Qu CK
Leukemia; 2017 Jun; 31(6):1415-1422. PubMed ID: 27840422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
